Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The National Institute Of Immunology currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is being reviewed by 1 distinct examiner, ROCHELLE, CIERRA MARIE. As the busiest examiner for the portfolio, ROCHELLE, CIERRA MARIE is responsible for the 1 busiest examiner pending office action, which is housed within 1 distinct art unit.
The prosecution profile for this entity is highly centralized, with all active work limited to 1 distinct examiner. Because the 1 pending office action is located in 1 distinct art unit, practitioners only need to navigate the specific requirements and standards of that single unit. ROCHELLE, CIERRA MARIE handles the 1 pending office action, serving as the sole point of contact for the current Biotechnology & Pharmaceuticals filings.
This level of concentration, featuring 1 pending office action and 1 distinct examiner, suggests a targeted patent strategy. The 1 distinct art unit involved will define the examination parameters for the 1 pending office action. Practitioners should focus on the specific tendencies of ROCHELLE, CIERRA MARIE, as she holds the 1 busiest examiner pending office action that constitutes the entire active portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROCHELLE, CIERRA MARIE | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18539826 | METHODS AND COMPOSITIONS FOR TREATING COLORECTAL CANCER WITH INDOXYL SULFATE | ROCHELLE, CIERRA MARIE | 42d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18539826 | METHODS AND COMPOSITIONS FOR TREATING COLORECTAL CANCER WITH INDOXYL SULFATE | ROCHELLE, CIERRA MARIE | 1627 | §101§103§112 | Final Rejection | 42d | Pending | Dec 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial